Divide and Conquer: A look behind the scenes of the EU pharmaceutical industry lobby

Heading ACTA and Access to Medicines: Flawed Process, Rationale and Agreement

Protect Access to Medicines: Say “No” to ACTA

Business Conduct Guidelines

Complaints Procedure (EN)

Procedimiento de Querellas

Klachtenprocedure (Complaints Procedure – Dutch)

Unlocking the Mysteries of Access to Clinical Trials Data in the EU

Call to EU Leadership on Global Health Research & Development


Statement on Medicines Patent Pool

Universal Access to Medicines for Non-Communicable Diseases

Drop in Pay-for-Delay Good for Access to Medicines in Europe

Resolution on Innovation and Access to Medical Technologies

Uso Racional: La influencia de la publicidad en el uso del medicamento

Statement on Conflicts of Interests delivered at WHA

Statement on EU India and EU Mercosur Free-Trade Negotiations

Medicines pay-for-delay back under the microscope

Transparency of European Medicines Regulation


Increasing Calls Within the EU for New Models of Medical Innovation

EMA Talks the ‘Conflicts of Interest’ Talk, but Will it Walk the Walk?

EU Citizens Get a Voice in Pharmacovigilance

Как распознавать продвижение лекарств и как к нему относиться: Практическое руководство

Comprender la promoción farmacéutica y responder a ella: Una guía práctica

Understanding & Responding to Pharmaceutical Promotion: A Practical Guide

WHO Should Refocus its Efforts on Wider Public Health Threats

Direct Patient Reporting of Adverse Drug Reactions

HAI Europe is Granted Full Membership by the European Medicines Agency


European Medicines’ Policy Where it Belongs

Unbiased medicines’ information: European best practices

Wyzwanie dla niezależnej informacji: dyrektywa w sprawie informowania pacjentów